Fundraising FoxSanti Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Santi Therapeutics
Sign up to see every warm intro you have to Santi Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Santi Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JR
Joshua ResnickNamed on SEC filing
MD
Milind DeshpandeNamed on SEC filing
SR
Simon ReadNamed on SEC filing
Board
DG
David GrayzelBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$178.6M disclosed across 4 rounds · 2020–2025
▶$120.1MraisedDec 2025 · 20 investors · PharmaceuticalsRule 506(b)
▶$120.1MraisedDec 2025 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Patrick TrojerExecutive Officer, Director
- Joshua ResnickDirector
- Jigar RaythathaDirector
- David GrayzelDirector
- Andrew HedinDirector
- Lorence KimDirector
- Shelley ChuDirector
- Christopher O'DonnellDirector
- Offering amount
- $120.1M
- Amount sold
- $120.1M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.6MraisedApr 2022 · 14 investors · PharmaceuticalsRule 506(b)
▶$42.6MraisedApr 2022 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shelley ChuDirector
- Simon ReadDirector
- Jigar RaythathaDirector
- Patrick TrojerExecutive Officer, Director
- Joshua ResnickDirector
- Christopher O'DonnelDirector
- Milind DeshpandeDirector
- David GrayzelDirector
- Offering amount
- $85.1M
- Amount sold
- $42.6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$10MraisedSep 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedSep 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joshua ResnickDirector
- David GrayzelDirector
- Milind DeshpandeExecutive Officer, Director
- Simon ReadDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedJul 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$6MraisedJul 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Milind DeshpandeExecutive Officer, Director
- Joshua ResnickDirector
- Nathaniel Brooks HorwitzDirector
- Offering amount
- $14M
- Amount sold
- $6M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Santi Therapeutics's investors?
- Santi Therapeutics's investors include Ascenta Capital.
- How much funding has Santi Therapeutics raised?
- Santi Therapeutics has disclosed $178.6M raised across 4 rounds.
- Where is Santi Therapeutics headquartered?
- Santi Therapeutics is headquartered in Waltham, US.